Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2023

Jan 18, 2024

BUY
$0.97 - $3.55 $679 - $2,485
700 New
700 $0
Q1 2018

May 11, 2018

SELL
$27.78 - $35.19 $161,124 - $204,102
-5,800 Reduced 95.08%
300 $0
Q4 2017

Jan 17, 2018

SELL
$23.33 - $35.01 $72,323 - $108,531
-3,100 Reduced 33.7%
6,100 $12,000
Q3 2017

Oct 17, 2017

BUY
$21.65 - $32.18 $199,180 - $296,056
9,200
9,200 $10,000

Others Institutions Holding CLLS

About Cellectis S.A.


  • Ticker CLLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,510,800
  • Market Cap $71M
  • Description
  • Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...
More about CLLS
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.